Abiomed announces brand-new data from the USpella IRB registry of Impella 2.

Abiomed announces brand-new data from the USpella IRB registry of Impella 2.5 patients Abiomed Inc Click to read more about the treatment . , a respected provider of breakthrough center support technologies, today announced new medical data from USpella, the initial U.S. Multicenter registry of Impella 2.5 sufferers analyzing the feasibility and safety of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention and treatment of acute myocardial infarction . USpella, presented at TCT 2009 by Brijeshwar Maini, M.D., co-seat, cardiovascular analysis, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Center & Vascular Group, evaluated data from 16 Impella 2.5 centers with IRB authorization and over 181 individuals from the a lot more than 1,000 reported commercial Impella 2.5 cases.